Biorestorative Therapies, Inc. (NASDAQ:BRTX) Sees Large Growth in Short Interest

Biorestorative Therapies, Inc. (NASDAQ:BRTX) saw a significant growth in short interest in February. As of February 13th, there was short interest totaling 1,226,671 shares, a growth of 826.1% from the January 29th total of 132,462 shares. Approximately 19.6% of the shares of the stock are short sold. Based on an average daily volume of 6,360,187 shares, the days-to-cover ratio is currently 0.2 days. Based on an average daily volume of 6,360,187 shares, the days-to-cover ratio is currently 0.2 days. Approximately 19.6% of the shares of the stock are short sold.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Biorestorative Therapies in a research note on Monday, December 29th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, Biorestorative Therapies presently has a consensus rating of “Sell”.

Institutional Investors Weigh In On Biorestorative Therapies

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Virtu Financial LLC lifted its stake in Biorestorative Therapies by 102.4% in the 3rd quarter. Virtu Financial LLC now owns 24,351 shares of the company’s stock worth $35,000 after purchasing an additional 12,319 shares in the last quarter. DRW Securities LLC acquired a new stake in shares of Biorestorative Therapies in the fourth quarter valued at approximately $55,000. Finally, Citadel Advisors LLC purchased a new position in Biorestorative Therapies during the third quarter worth approximately $152,000. Institutional investors and hedge funds own 69.38% of the company’s stock.

Biorestorative Therapies Trading Down 3.2%

NASDAQ:BRTX traded down $0.01 during trading hours on Friday, hitting $0.22. 3,229,543 shares of the stock were exchanged, compared to its average volume of 8,610,867. The firm’s fifty day moving average price is $0.92 and its 200 day moving average price is $1.25. Biorestorative Therapies has a 52-week low of $0.19 and a 52-week high of $2.10. The company has a market cap of $2.03 million, a P/E ratio of -0.15 and a beta of 0.39.

Biorestorative Therapies Company Profile

Biorestorative Therapies Inc (NASDAQ: BRTX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of regenerative tissue therapy products. The company leverages a proprietary universal allogeneic cell technology platform to create high-potency cell therapy candidates designed to promote tissue repair, reduce inflammation and accelerate healing in areas damaged by disease or medical treatment.

Its lead development program targets radiation-induced oral mucositis (RIOM), a painful and dose-limiting side effect experienced by head and neck cancer patients undergoing radiotherapy.